SLIT2 promoter methylation analysis in neuroblastoma, Wilms' tumour and renal cell carcinoma by Astuti, D et al.
SLIT2 promoter methylation analysis in neuroblastoma, Wilms’
tumour and renal cell carcinoma
D Astuti
1,7, NF da Silva
1,2,7, A Dallol
1, D Gentle
1,2, T Martinsson
3, P Kogner
4, R Grundy
1,5, T Kishida
6, M Yao
6,
F Latif
1,2 and ER Maher*,1,2
1Section of Medical and Molecular Genetics, Department of Paediatrics and Child Health, University of Birmingham, The Medical School, Edgbaston,
Birmingham B15 2TT, UK;
2Cancer Research UK Renal Molecular Oncology Research Group, University of Birmingham, The Medical School, Edgbaston,
Birmingham B15 2TT, UK;
3Department of Clinical Genetics, Gothenburg University, Sahlgrenska University Hospital/Ostra, S-416 85 Gothenburg,
Sweden;
4Childhood Cancer Research Unit, Department of Women and Child Health, Karolinska Institute, Karolinska Hospital, S-171 76 Stockholm,
Sweden;
5Department of Paediatric Oncology, Birmingham Children’s Hospital, UK;
6Yokohama City University School of Medicine, Yokohama, Japan
The 3p21.3 RASSF1A tumour suppressor gene (TSG) provides a paradigm for TSGs inactivated by promoter methylation rather than
somatic mutations. Recently, we identified frequent promoter methylation without somatic mutations of SLIT2 in lung and breast
cancers, suggesting similarities between SLIT2 and RASSF1A TSGs. Epigenetic inactivation of RASSF1A was first described in lung and
breast cancers and subsequently in a wide range of human cancers including neuroblastoma, Wilms’ tumour and renal cell carcinoma
(RCC). These findings prompted us to investigate SLIT2 methylation in these three human cancers. We analysed 49 neuroblastomas
(NBs), 37 Wilms’ tumours and 48 RCC, and detected SLIT2 promoter methylation in 29% of NB, 38% of Wilms’ tumours and 25% of
RCC. Previously, we had demonstrated frequent RASSF1A methylation in the same tumour series and frequent CASP8 methylation in
the NB and Wilms’ tumour samples. However, there was no significant association between SLIT2 promoter methylation and
RASSF1A or CASP8 methylation in NB and RCC. In Wilms’ tumour, there was a trend for a negative association between RASSF1A and
SLIT2 methylation, although this did not reach statistical significance. No associations were detected between SLIT2 promoter
methylation and specific clinicopathological features in the tumours analysed. These findings implicate SLIT2 promoter methylation in
the pathogenesis of both paediatric and adult cancers and suggest that further investigations of SLIT2 in other tumour types should be
pursued. However, epigenetic inactivation of SLIT2 is less frequent than RASSF1A in the tumour types analysed.
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Methylation of CpG dinucleotides in the promoter regions of
tumour suppressor genes (TSGs) producing transcriptional silen-
cing is a major mechanism of TSG inactivation in many human
cancers (Baylin et al, 1998; Jones, 1999; Tycko, 2000; Costello and
Plass, 2001). The frequency of TSG inactivation by de novo
methylation varies between TSGs and between cancers. Initially,
epigenetic silencing of TSGs was reported as an alternative, but a
minor mechanism of inactivation for TSGs such as RB1 and VHL
(Greger et al, 1994; Herman et al, 1994). However, recently a new
class of TSGs has been recognised for which epigenetic silencing is
the overwhelming mechanism of inactivation and somatic muta-
tions are rare. This paradigm is exemplified by the RASSF1A
3p21.3 TSG, which is methylated in a wide range of human cancers
(Dammann et al, 2000; Agathanggelou et al, 2001; Astuti et al,
2001; Burbee et al, 2001; Dreijerink et al, 2001; Morrissey et al,
2001).
Recently, we identified frequent promoter region hypermethyla-
tion of SLIT2 in lung and breast cancers (Dallol et al, 2002a). SLIT2
maps to 4p15.2 and encodes a human orthologue of the Drosophila
Slit protein, a secreted glycoprotein, which regulates axon
guidance, branching and neural migration during development
of the central nervous system (Brose et al, 1999). Slit exerts its
effects as a diffusible chemorepellent via its receptor Roundabout
(Robo) (Stein and Tessier-Lavigne, 2001). In mammals, three
distinct slit genes (slit1, slit2, and slit3) and three distinct robo
genes (robo1, robo2, rig-1) have been identified. In lung and breast
cancers, SLIT2 mutations were not detected despite frequent
promoter methylation (similar to RASSF1A) (Dallol et al, 2002a).
Methylation of RASSF1A was first reported in lung and breast
cancers, but subsequently we and others demonstrated RASSF1A
methylation in renal cell carcinoma (RCC) and in common
childhood tumours such as neuroblastoma (NB) and Wilms’
tumour (Astuti et al, 2001; Dreijerink et al, 2001; Lo et al, 2001;
Morrissey et al, 2001; Wagner et al, 2002). These findings
prompted us to extend our studies of SLIT2 inactivation by
studying SLIT2 promoter methylation in NB, Wilms’ tumour and
RCC.
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sMATERIALS AND METHODS
Patients and samples
A total of 134 tumour samples were analysed (49 NBs, 37 primary
Wilms’ tumours and 48 adult RCC). Details of the tumours have
been published previously (Astuti et al, 2001; Wagner et al, 2002).
DNA was extracted from tumour and normal tissues (blood or
matched kidney) by standard methods.
Sodium bisulphite modification
Sodium bisulphite modification was carried out using an adapted
method (Herman et al, 1996). Genomic DNA (0.5–1mg) was
denatured at 371C for 10min in 0.3 M NaOH. Unmethylated
cytosines were sulphonated by incubation in 3.12 M sodium
bisulphite/1 M hydroquinone (pH 5) at (951C (30s) 501C
(15min)) 20 cycles. The resulting sulphonated DNA was purified
using the Wizard DNA clean-up system (Promega, Southampton,
UK), according to the manufacturer’s instructions, except that
DNA was eluted with distilled water (50ml) at room temperature.
Following elution, DNA was desulphonated in 0.3 M NaOH for
5min at room temperature, then the DNA was precipitated with
NaOAc (5mlo f3 M) and ethanol (125ml of 100%) overnight at
 201C and resuspended in 50ml distilled water.
Methylation-specific polymerase chain reaction (PCR)
The CpG island within the putative SLIT2 promoter has been
described in detail previously (Dallol et al, 2002a). Methylation
Specific PCR (MSP) analysis was performed essentially using
primers and conditions as described in Dallol et al, 2002a).
Combined Bisulphite Restriction Analysis (CoBRA) analysis was
carried out as follows. In brief, the putative promoter region from
nt  761 to  212 (relative to the translation start site) was
amplified with primers reported previously (Slit2MODF-(50-
GGGAGGTGGGATTGTTTAGATATTT-30 and Slit2MODR2 (50-
CAAAAACTCCTTAAACAACTTTAAATCCTAAAA-30). From this
reaction, one out of 50 of the volume was used as a template for a
nested PCR with primers Slit2MODF as above and Slit2MODR (50-
ACTAAAACTTCCAACAACTACTAAAATACAAAAA-30) to pro-
duce a 418bp product (PCR conditions: 951C for 10min, followed
by 30–40 cycles of 1min denaturation at 951C, 1min annealing at
541C, and 2min extension at 741C). PCR products were then
digested by BstU1 restriction enzyme to assess the methylation
status of samples.
Sequencing of PCR products
MSP and CoBRA products were excised from agarose gels and
extracted using the QIAquick Gel Extraction Kit (Qiagen, Crawley,
UK, West Sussex), according to the manufacturer’s instructions.
Products were confirmed by direct sequencing from the forward
PCR primer using ABI Prism
s BigDyetTerminators Cycle
Sequencing Kit according to the manufacturer’s instructions and
run using ABI 377 automatic sequencers.
5-aza-20-deoxycytidine treatment of cell lines
5-aza-20-deoxycytidine (5-aza-dC, Sigma, Poole, UK) was freshly
prepared in ddH2O (at 2mgml
 1) and filter-sterilised. A total of
0.5–1 10
6 cells were plated in 75cm
2 flask in RPMI 1640 media
supplemented with 10% foetal calf serum and left to settle for 24h
(day 0). Kidney and NB cell lines were treated with 2mM 5-aza-dC
for a total of 5 days. Kidney and NB have a different rate of growth.
Kidney tumour cell lines were treated with 5-aza-dC on days 1, 3
and 5 and harvested on day 6, with a medium change in days 2 and
4 (Nojima et al, 2001). Neuroblastoma cell lines were treated on
days 1 and 4. The medium was changed 24h after treatment and
then every 3 days. RNA was prepared after treatment using the
RNeasy kit (Qiagen) according the manufacturer’s guidelines.
SLIT2 gene expression was ascertained by RT–PCR using the
primers 50-GGTGTCCTCTGTGATGAAGAG-30 and 50-GTGTTTAG
GAGACACACCTCG-30, resulting in a product size 387bp. As a
control, the GAPDH primers used were: 50-GACCCCTTCAT
GACCTCAACTACA-30 and 50-CTAAGCAGTTGGTGGTGCAGGA-
30, resulting in a PCR product of 369bp.
Microsatellite repeat analysis – loss of heterozygosity
By searching GDB and the UCSC assembly of the human genome
sequence, we identified D4S1546 as the closest marker to SLIT2
(within 100kb). A 4p15.2 allele loss was assessed with the D4S1546
marker. (PCR conditions: 951C for 5min followed by 35 cycles of
951C for 30s, 521C (551C) for 30s, and 721C for 30s and a final
extension of 10min at 721C).
Statistical analysis
Fisher’s exact test was used as appropriate. P-values of o0.05 were
considered to be statistically significant.
RESULTS
SLIT2 methylation status in NB
SLIT2 promoter methylation status was analysed in 49 primary
NB tumours and 29% (14 out of 49) demonstrated SLIT2 CpG
island promoter methylation (Figure 1A). Promoter CpG island
methylation was confirmed by direct sequencing of five clones
from one tumour (Figure 4B). We also analysed eight NB cell lines
for SLIT2 methylation by restriction digestion and two cell lines
(SK-N-F1 and SK-N-SH) were found to be partially methylated.
SLIT2 methylation was detected in one out of 49 corresponding
normal blood samples.
To investigate the 4p15.2 allelic status of NBs with SLIT2
methylation, we typed 13 methylated tumours for loss of
heterozygosity (LOH) at D4S1546 that maps close to SLIT2. In all,
33% (four out of 11) of informative tumours demonstrated allele
loss consistent with homozygous SLIT2 inactivation (Figure 2).
SLIT2 promoter methylation is associated with transcriptional
silencing To determine the relationship of SLIT2 promoter region
CpG island methylation and SLIT2 transcript expression in the NB
cell lines SK-N-F1 and SK-N-SH, we treated the cells with the
demethylating agent, 5-aza-dC, for 5 days. The 5-aza-dC treatment
significantly increased SLIT2 expression in both cell lines, but
there was little or no change in the expression of GAPDH
expression after the 5-aza-dC treatment (Figure 3).
SLIT2, CASP8 and RASSF1A methylation status in NB Pre-
viously, we reported that RASSF1A and caspase 8 (CASP8)
promoter methylation occurred in 55 and 40% of NBs, respec-
tively. To determine whether there was any relationship between
SLIT2 promoter methylation and de novo methylation of RASSF1A
and CASP8 promoters, we compared the frequencies of RASSF1A
and CASP8 methylation in tumours with and without SLIT2
methylation (using previously published RASSF1A and CASP8
methylation data (Astuti et al, 2001). CASP8 methylation was
detected in 36% of SLIT2 methylated and 41% SLIT2 unmethylated
tumours (P¼1.0). RASSF1A promoter methylation was more
frequent in tumours with SLIT2 promoter methylation (77 vs 59%),
but this did not reach statistical significance (P¼0.32).
Neuroblastoma clinicopathological features and SLIT2 methylation
status We compared the results of SLIT2 methylation status in
our tumour series to the previously reported results for allelic loss
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et al, 1997). There was no correlation between SLIT2 methylation
and 1p allele loss (22% of SLIT2 methylated and 22% of
unmethylated tumours, P¼1.0), 3p allele loss (25 vs 12%,
P¼0.57), 17q gain (50 vs 65%, P¼0.62) or N-myc amplification
status (15 vs 13%, P¼1.0). There was no association between
tumour stage and SLIT2 methylation status: SLIT2 methylation was
present in 33% of stage 1, 2 and 4S tumours and in 26% of stage 3
and 4 tumours (P¼0.73).
Methylation analysis of SLIT2 in primary Wilms’ tumours
Next, we proceeded to analyse SLIT2 promoter methylation status
in 37 Wilms’ tumours that had been investigated previously for
RASSF1A and CASP8 promoter methylation status (Wagner et al,
2002 and unpublished observations). In total, 38% (14 out of 37)
Wilms’ tumours demonstrated SLIT2 CpG island promoter
methylation (Figure 1B). Promoter CpG island methylation was
confirmed by direct sequencing in one tumour (Figure 4B). All
SLIT2 methylated tumours contained unmethylated SLIT2 alleles
that might be attributable to the presence of contaminating normal
tissue (tumour samples were not microdissected). SLIT2 methyla-
tion was detected in zero of six normal tissue samples
corresponding to the methylated tumours.
To investigate the 4p15.2 allelic status of Wilms’ tumours with
SLIT2 methylation, we typed six methylated tumours for LOH at
D4S1546. None of three informative tumours demonstrated
D4S1546 allele loss.
Methylation of SLIT2 and other cancer genes in primary Wilms’
tumours To investigate the relationships between SLIT2 promo-
ter methylation and de novo methylation of RASSF1A and CASP8,
we compared the frequencies of CASP8 and RASSF1A methylation
in tumours with and without SLIT2 methylation. In tumours with
SLIT2 methylation, CASP8 and RASSF1A were methylated in 43%
(six out of 14) and 36% (five out of 14), respectively. In tumours
without SLIT2 methylation, CASP8 and RASSF1A promoter
methylation was detected in 39% (nine out of 23) and 70% (16
200 bp
200 bp
BstU1digest
Tumour  Normal
Un CU n C
418 bp
BstU1digest
SKRC 18 SKRC 47
Un C Un       C
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107N 107T 191N 191T 113T 133N 133T
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90N 90T 244N 244T 142T 219T
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C
Figure 1 Methylation analysis of SLIT2 by MSP in neuroblastoma tumours (A) and Wilm’s tumours (B) and by CoBRA in RCC cell lines and primary
kidney tumours and corresponding normal tissue (C). (A and B). Bisulphite-modified DNA was amplified with primers specific for unmethylated (U) and
methylated (M) DNA. Tumours positive for SLIT2 methylation are depicted by the presence of a 160bp product when using specific primers for methylated
DNA. N¼blood; T¼tumour tissue. (C) Bisulphite-modified DNA was amplified by nested PCR and then digested with BstU1 restriction enzyme for 4h at
601C, uncut (Un) and cut (C). SKRC 18 is partially methylated while SKRC 47 is unmethylated. The RCC tumour shown above is completely methylated.
N N
125 133 162
T T N T
Figure 2 Genotyping of marker D4S1546 in neuroblastoma tumours. N
and T, matched DNA samples from blood (N) and tumour tissue (T).
Tumours 125 and 162 showed LOH, while tumour 133 shows retention of
allele. The position of the lost allele is indicated by the arrows.
SK-N-SH
−
SKRC 39 SKRC 18 SKRC 47
387 bp SLIT2
GAPDH 369 bp
5-aza-dc + − + − + − +
Figure 3 SLIT2 expression by RT–PCR in neuroblastoma (SK-N-SH)
and renal cell carcinoma cell lines (SKRC 39, SKRC 18 and SKRC 47),
without ( ) and with (þ) 5-aza-20-deoxycytidine (5-aza-dc) treatment.
Cells were treated for up to 5 days with 5-aza-dc and expression was
analysed by RT–PCR. The methylated cell lines (SK-N-SH, SKRC 39, SKRC
18) show an increase in SLIT2 expression after 5-aza-dc treatment, while
the unmethylated cell line SKRC 47 presents no changes in SLIT2
expression before and after 5-aza-dc treatment.
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sout of 23), respectively. Thus, although there was no association
between SLIT2 and CASP8 methylation, there was an inverse
relationship between SLIT2 and RASSF1A methylation, although
this did not reach statistical significance (P¼0.09).
SLIT methylation status and clinicopathological status
The frequency of relapse in Wilms’ tumours with SLIT2
methylation was similar to that without SLIT2 methylation
(21% (three out of 14) and 17% (four out of 23),
respectively), and there was no significant association between
SLIT2 methylation and advanced stage tumours (the frequency of
stage 3 and 4 tumours in the SLIT2 methylated and unmethylated
groups was 45% (five out of 11) and 63% (12 out of 19),
respectively).
Methylation analysis of SLIT2 in primary RCC
We detected SLIT2 promoter methylation in 25% (12 out of 48)
primary RCC and in 75% (six out of eight) RCC cell
lines (Figure 1C). Promoter CpG island methylation was confirmed
by direct sequencing of five clones from RCC cell lines and 2
tumours (Figure 4A). SLIT2 promoter methylation was also
detected in one out of 12 of the matching normal kidney tissue
samples for methylated tumours. All RCC with SLIT2 methylation
also contained unmethylated SLIT2 alleles, which might be
attributable to the presence of contaminating normal tissue
(tumour samples were not microdissected). Loss of heterozygosity
at D4S1546 was not detected in 10 informative RCC with SLIT2
methylation.
SLIT2 promoter methylation is associated with transcriptional
silencing in an RCC cell line We investigated the possible
association between the SLIT2 promoter region CpG island
methylation and SLIT2 transcript expression in a panel of RCC
cell lines (SKRC 18, SKRC 39, SKRC 45, SKRC 47, SKRC 54, KTCL
26,UMRC-2 and 786-0). Cells were treated with the demethylating
agent 5-aza-dC for 5 days. Except for SKRC 45 and SKRC 47 (both
unmethylated for SLIT2), SLIT2 expression was significantly
increased in the kidney tumour cell lines after 5-aza-dC treatment.
GAPDH expression levels were equal in both 5-aza-dC-treated and
untreated cell lines (Figure 3).
Methylation status of SLIT2 and inactivation of RASSF1A and
VHL in primary RCC Previously, we analysed primary
RCC for RASSF1A methylation and inactivation of the
VHL tumour suppressor gene. There was no association between
SLIT2 methylation and the presence of VHL mutation in clear cell
RCC, and the frequency of RASSF1A methylation was similar in
RCC with and without SLIT2 methylation (25 and 21%,
respectively).
SLIT2 methylation status and clinicopathological status The
frequency of SLIT2 methylation in clear cell RCC (24%, nine out
of 37) was similar to that found in all tumour types. There was no
significant association between SLIT2 methylation status and grade
or TNM status.
DISCUSSION
Previously, we (a) identified SLIT2 promoter methylation in 53%
non-small-cell lung cancer, 36% small-cell lung cancer and
43% of breast cancers, (b) demonstrated that promoter
methylation is associated with reversible transcriptional silencing
and (c) determined that restoration of SLIT2 expression sup-
pressed tumour growth in in vitro studies (Dallol et al, 2002a).
Thus having established SLIT2 as a lung and breast cancer
suppressor gene, we have now identified frequent SLIT2 hyper-
methylation in paediatric cancers and in RCC and, recently, in 59%
of gliomas (Dallol et al, 2003). Slit protein binds to the roundabout
receptor and acts as a midline repellent to guide axonal
development during embryogenesis (Rajagopalan et al, 2000;
Simpson et al, 2000; Wong et al, 2001) In humans, three SLIT
orthologues have been identified, but to date only SLIT2 has been
implicated in cancer. In mice, Robo1 inactivation produces delayed
lung maturation and bronchial hyperplasia (Xian et al, 2001) and
we have demonstrated de novo ROBO1 promoter methylation in
19% primary invasive breast carcinomas and 18% primary clear
cell RCC, although somatic mutations were not identified (Dallol
et al, 2002b).
The characterisation of tumour-specific TSG methylation
profiles provides insights into the molecular pathology of the
tumour and can be used to establish tumour-specific methylation
profiles (Esteller et al, 2001a). It is anticipated that such profiles
will be useful for diagnosis and clinicopathological classification.
In colorectal cancer, the identification of a subset of tumours with
widespread de novo methylation of TSG and mismatch repair
genes (‘the methylator phenotype’) (Toyota et al, 1999) has been of
considerable interest and it is unclear as to whether similar
subtypes will be a feature of other cancers.
The molecular pathology of sporadic NB has been investigated
extensively by molecular cytogenetic and LOH analysis. Frequent
alterations include N-myc amplification (20–25%) and gain of
genetic material at 17q23–qter (B50% of tumours). Neuroblas-
CpG
NB107
WT244
Unmethylated
Partially methylated
Fully methylated
SKRC 39
SKRC 18
SKRC 47
A
B
15 16 17 18 19 20 21 22 23 24 25 26 27 28
Figure 4 SLIT2 methylation profile. Illustration of the SLIT2 methylation pattern detected in (A) kidney tumour cell lines (SKRC 39, SKRC 18 and SKRC
47) and (B) neuroblastoma tumours (NB107) and Wilm’s tumours (WT244). The CpG island numbered according to Dallol et al (2002a).
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stoma TSGs have been mapped by LOH studies to 1p36 (B35% in
primary tumours show LOH), 11q23 (44%), 14q23–qter (22%) and
3p (15%) (Ejeskar et al, 1998; Maris and Matthay, 1999). However,
specific gene mutations have not been defined, although we did
identify RASSF1A methylation in 55% of NBs and that CASP8
methylation occurs in B50% of tumours (Teitz et al, 2000; Astuti
et al, 2001). Caron et al (1996) reported 4p allele loss in B20% of
NB and we have now identified promoter methylation of the 4p15.2
candidate TSG SLIT2 in 29% of NBs. Thus, epigenetic inactivation
of SLIT2 is a common feature of NB, although less frequent than
methylation of CASP8 and RASSF1A. Harada et al (2002b) reported
that NB patients with CASP8 methylation were older than those
without tumour methylation, but to date, CASP8, RASSF1A or
SLIT2 methylation has not been associated with specific clinico-
pathological, cytogenetic or molecular features of NB. However,
very large studies may be needed to identify significant prognostic
correlations in the presence of a large number of potential
variables. We did not find clear evidence of a ‘methylator
phenotype’, although methylation of RASSF1A was more common
in tumours with SLIT2 methylation than in those without SLIT2
methylation and Harada et al (2002b) reported an association
between RASSF1A and CASP8 methylation in NB tumours.
However, we found no association between SLIT2 and CASP8
methylation. The frequency of SLIT2 methylation in NB was less
than that for RASSF1A and CASP8, but is still a significant finding
as other candidate TSGs that demonstrate frequent promoter
methylation in some cancers (e.g. p16INK4A, MGMT, RARa ˆ,
DAPK, APC, GSTP1, CDH1 and CDH13) are rarely methylated in
NB (Harada et al, 2002a).
Although de novo methylation and silencing of H19 in
Wilms’ tumours was first reported some years ago (Steenman
et al, 1994; Taniguchi et al, 1995), epigenetic changes
have not been investigated in great detail in Wilms’ tumour.
Recently, we reported frequent CASP8 (43%) and RASSF1A
(56%) promoter methylation in Wilms’ tumours and the
present study has demonstrated that SLIT2 methylation represents
a further frequent epigenetic change in Wilms’ tumours. To date,
we have not identified an association between CASP8, RASSF1A
and SLIT2 methylation in individual tumours, so there is little
evidence of a methylator phenotype in a subset of Wilms’ tumours.
Indeed there was a negative, albeit statistically insignificant,
correlation between RASSF1A and SLIT2 methylation. This finding
merits further investigation as it could indicate that the
simultaneous inactivation of specific TSGs might be disadvanta-
geous in specific cancer types. Although p16
INK4a(CDKN2a)
promoter methylation has been reported in advanced stage Wilms’
tumours (Arcellana-Panlilio et al, 2000), this trend was not
significant in our series, and to date no specific clinicopathological
features have been associated with SLIT2, CASP8 and RASSF1A
methylation. In our Wilms’ tumour series, the frequency of SLIT2
promoter methylation in Wilms’ tumours was similar to that for
CASP8 but higher than that for TSGs, which may show frequent
promoter methylation in other tumour types, for example, MGMT
(30%), NORE1A (15%), p14
ARF (15%), p16
INK4a (10%), DAPK
(11%), CRBP1 (9%), RARB2 (0%), CDH13 (0%) and CDH1 (3%)
(Morris et al, 2003).
Renal cell carcinoma is the most common adult tumour
and the majority (B75%) of RCC are classified as clear cell
RCC, with papillary being the most frequent nonclear cell
histopathological subtype (B15% of all cases) (Storkel and van
den Berg, 1995). The most frequent genetic change in RCC is
somatic inactivation of the VHL TSG (usually be mutation and
loss, but promoter methylation may also occur), although VHL
inactivation is specific for clear cell RCC (Foster et al, 1994; Gnarra
et al, 1994; Clifford et al, 1998). Combining the results of the
current study with previous investigations, frequent epigenetic
changes (X20%) in RCC include promoter methylation of
RASSF1A, TIMP3, DAPK, SLIT2, MT1G and GSTP1 (Esteller et al,
2001a; Nojima et al, 2001, Dreijerink et al, 2001; Morrissey et al,
2001, Morris et al, 2003). In contrast, promoter methylation not at
(or rarely at) SDHB, RARB2, p16
INK4a and CDH13 is uncommon
(o5%). To date, apart from VHL, none of the epigenetic changes
in RCC have been associated with specific clinicopathological
features.
The failure to detect an association between clinicopathological
stage and SLIT2 methylation status could indicate that
SLIT2 methylation is an early event in tumorigenesis. In tumours
such as colorectal cancer, where there is a well-validated
adenoma–carcinoma sequence, it is possible to define the
genetic changes associated with different stages of tumorigenesis.
However, in sporadic cases of NB, Wilms’ tumour and RCC,
there is generally no well-defined pathway from precursor
lesion to tumour (although nephroblastomatosis may be
present in patients with Beckwith–Widemann syndrome and
‘early lesion RCC’ has been described in von Hippel-Lindau
disease). Hence, we are unable to precisely define when SLIT
methylation occurs in the pathogenesis of these tumours. However,
it is known that TSG inactivation may be an early event in
tumorigenesis. Thus, methylation may be the ‘second hit’ in
familial cancer syndrome tumours (Prowse et al, 1997, Esteller
et al, 2001b). Furthermore, in sporadic and familial adenomatous
polyposis coli, TSG CpG island methylation may be
detected in the earliest precursor lesion in colorectal carcinogen-
esis, aberrant crypt foci (Chan et al, 2002). Similarly, Zo ¨chbauer-
Mu ¨ller et al (2001) suggested that TSG methylation may be a
preneoplastic change in non-small-cell lung cancer. We have
analysed previously RASSF1A promoter methylation status in
normal, ductal-carcinoima-in situ (DCIS) and breast cancer trios.
RASSF1A promoter hypermethylation was detected in 65% of
invasive cancers and in 42% of corresponding DCIS but in none of
the normal breast samples (Honorio et al, 2003). In all, 30% of
DCIS without invasive breast cancer also underwent RASSF1A
promoter hypermethylation, suggesting that inactivation of
RASSF1A by CpG island methylation is an early event in breast
tumorigenesis. Preliminary unpublished data also reveal SLIT2
methylation in DCIS samples (RE Dickinson and F Latif,
unpublished). Thus, there is evidence that SLIT2 hypermethylation
can be implicated in early tumorigenesis.
In breast and lung cancers, TSG promoter methylation SLIT2
appears to resemble TSGs such as RASSF1A, as epigenetic
inactivation is more frequent than somatic mutations. RASSF1A
methylation has been reported in a wide range of human cancers.
We have demonstrated that SLIT2 methylation is common in
paediatric and adult cancers, and further analysis of additional
tumour types seems indicated. Frequent 4p allele loss has been
reported in cancers that demonstrate SLIT2 methylation such as
lung, breast and NB, and also in cancers in which SLIT2
methylation status has not been investigated including colorectal,
bladder and head and neck cancers (Knowles et al, 1994; Rosin
et al, 1995; Gryfe et al, 1997; Pershouse et al, 1997; Yustein et al,
1999; Girard et al, 2000). During development, the SLIT2 protein
functions as a secreted chemorepellent so that restoration of SLIT2
function by reversal of epigenetic inactivation or administration of
SLIT2 agonists might provide novel therapeutic opportunities for
human cancers.
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